Skip to main content

Viatris Inc Q3 FY2026 results

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Viatris Inc reported revenue of $3.75 billion, down 0.3% from a year earlier, net income of −$325 million and diluted earnings per share of −$0.28 against −$0.11 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 5 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Viatris Inc Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$3.75B$3.76B−0.3%
Gross profit$1.44B$1.37B+4.8%
Gross margin38.4%36.5%+1.9 pts
Operating income$261.5M$178.8M+46.3%
Operating margin7.0%4.8%+2.2 pts
Net income−$325.3M——
Diluted EPS−$0.28−$0.11—
Operating cash flow$899.4M$744.9M+20.7%
Capital expenditure$85.70M$86.80M−1.3%
Free cash flow$813.7M$658.1M+23.6%

Operating KPIs for the quarter

Viatris Inc operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Brands revenue$2.5Bup 1.0%
Generics revenue$1.3Bdown 2.9%
Lipitor revenue$451.9Mup 14.1%
Norvasc revenue$190.2Mup 5.8%
EpiPen® Auto-Injectors revenue$155.8Mdown 0.9%
Lyrica ® revenue$114.2Mdown 9.7%
Creon ® revenue$98.1Mup 5.4%
Viagra ® revenue$94.1Mdown 10.6%
Influvac ® revenue$90.6Mdown 27.8%
Zoloft ® revenue$78.8Mup 18.0%
Yupelri ® revenue$71.5Mup 0.1%
Celebrex ® revenue$70.2Mdown 4.2%
Effexor ® revenue$63.9Mdown 4.9%
Xalabrands revenue$43.9Mup 13.7%
Xanax ® revenue$36.6Mup 7.0%
Amitiza ® revenue$36.4Mdown 10.8%
Dymista ® revenue$35.4Mup 4.7%
Developed Markets Segment revenue$2.2Bdown 1.8%
Greater China revenue$702.6Mup 14.2%
Emerging Markets Segment revenue$531.1Mdown 7.1%

Earlier quarters

Viatris Inc results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$3.75B−0.3%−$0.28
Q2 FY202630 Jun 2026$3.76B+4.9%−$0.10
Q1 FY202631 Mar 2026$3.52B+8.1%$0.15
Q4 FY202531 Dec 2025$3.70B+5.0%—
Q3 FY202530 Sep 2025$3.76B+0.2%−$0.11
Q2 FY202530 Jun 2025$3.58B−5.6%$0.00
Q1 FY202531 Mar 2025$3.25B−11.2%−$2.55
Q4 FY202431 Dec 2024$3.53B−8.1%—

More on Viatris Inc: financial statements · revenue · earnings per share

VTRS's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.